Skip to main content
. 2016 Jun 30;7(31):49334–49348. doi: 10.18632/oncotarget.10340

Figure 7. Kaplan-Meier curves showing disease free survival according to the expression of V-ATPase V1E1 and p-PKM2.

Figure 7

(A) Box plot distribution of V1E1 immunohistochemical scores in ESCC patients with high p-PKM2 expression (IHC score ≥ 3, n = 66) or low p-PKM2 expression (IHC score ≤ 2, n = 236). Spearman's rank correlation test. Plots were scaled by dividing each median value. (B) Disease-free survival curve among patients with ESCC expressing low p-PKM2 on the basis of V-ATPase V1E1 expression status (low V1E1, IHC score ≤ 2, n = 99; high V1E1, IHC score ≥ 3, n = 137). (C) Disease-free survival curve among patients with ESCC expressing high p-PKM2 on the basis of V-ATPase V1E1 expression status (low V1E1, IHC score ≤ 2, n = 14; high V1E1, IHC score ≥ 3, n = 52). Log-Rank test.